FDA Expands Pediatric Roflumilast Use - Quiz - MDSpire

FDA Expands Pediatric Roflumilast Use

The expanded indication is supported by pharmacokinetic, safety, tolerability, exploratory efficacy, and long-term safety data from studies in children aged 2 to 5 years.

  • By

  • Kathryn Wighton

  • June 30, 2026

  • 3 min

Share

Original Source(s)

FDA Expands Pediatric Roflumilast Use

  • by Kathryn Wighton

  • June 30, 2026

Related Content

Triglycerides Linked to Psoriasis Risk

Genetically predicted triglyceride levels were associated with higher odds of psoriasis, while genetically predicted total fatty acid levels were not, in a two-sample Mendelian randomization analysis.

Pediatric Dermatology Clinic now accepting referrals for complex cases

This program provides subspecialty expertise in the diagnosis and management of complex pediatric dermatologic diseases.

  • May 14, 2026

  • 1 min
Informatics-Based Psychotherapeutic and Psychiatric Interventions in Dermatology: Scoping Review of Impacts on Skin Disease Severity and Mental Health Outcomes